| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3995144 | The Lancet Oncology | 2008 | 7 Pages |
Abstract
SummaryVenous thromboembolism (VTE) is common in malignant disease and is associated with substantial morbidity and mortality. Recently, VTE has received increased attention as a result of the use of newer drugs, such as erythropoietin-stimulating agents or antiangiogenic drugs, which increase the risk of this condition. Several reviews have been published on VTE in cancer, but none have specifically focused on cervical cancer. In this review, we focus on the incidence of VTE, patient, tumour, and treatment-related risk factors for VTE, and treatment and prevention of VTE in the setting of cervical cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Lisa Barbera, Gillian Thomas,